Press Releases

06-24-2022	Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
06-22-2022	Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
06-16-2022	Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
06-15-2022	Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
05-18-2022	Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
05-11-2022	Pliant Therapeutics to Participate in Upcoming Investor Conferences
05-09-2022	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
05-05-2022	Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
05-03-2022	Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
05-02-2022	Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

Investors & Media